Market Place
Sourcing Support
Merck says Keytruda injection on par with approved IV version in trial
20 Nov 2024 //
FIERCE PHARMA
Merck Receives CHMP Opinion for KEYTRUDA® in MPM
15 Nov 2024 //
BUSINESSWIRE
Citius Pharma Announces Promising Pembrolizumab Trial Results
11 Nov 2024 //
PR NEWSWIRE
Medicenna Announces Positive MDNA11 Data with KEYTRUDA® at SITC
11 Nov 2024 //
GLOBENEWSWIRE
BeyondSpring Presents Phase 2 Efficacy of Pembrolizumab Combo
11 Nov 2024 //
GLOBENEWSWIRE
Hookipa Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
11 Nov 2024 //
GLOBENEWSWIRE
Compugen to Present COM701, COM902 + Pembrolizumab Data at SITC
05 Nov 2024 //
PR NEWSWIRE
Akeso Enrolls First Patient in Phase 3 HNSCC Trial with Ivonescimab
30 Oct 2024 //
PR NEWSWIRE
Merck, Moderna Launch Phase 3 Trial for NSCLC Treatment
28 Oct 2024 //
BUSINESSWIRE
Merck’s KEYTRUDA® Receives New Approvals For Gynecologic Cancers
24 Oct 2024 //
BUSINESSWIRE
Exelixis And Merck Sign Clinical Development Collaboration
14 Oct 2024 //
BUSINESSWIRE
Merck`s Keytruda stages comeback in head and neck cancer
08 Oct 2024 //
FIERCE PHARMA
BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda
04 Oct 2024 //
FIERCE PHARMA
ABL Bio Announces Clinical Collaboration For ABL103 with Keytruda
04 Oct 2024 //
PR NEWSWIRE
Cue Biopharma Announces Presentations At SITC Annual Meeting
04 Oct 2024 //
GLOBENEWSWIRE
Merus Doses First Patient In Ph 3 Trial Of Petosemtamab
30 Sep 2024 //
GLOBENEWSWIRE
Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study
26 Sep 2024 //
PRESS RELEASE
Merck`s KEYTRUDA Approved In Japan For NSCLC And Carcinoma
25 Sep 2024 //
BUSINESSWIRE
Japan Approves PADCEV With KEYTRUDA For Urothelial Cancer
24 Sep 2024 //
PR NEWSWIRE
Merck Receives Positive EU CHMP Opinions for KEYTRUDA
20 Sep 2024 //
BUSINESSWIRE
FDA Approves KEYTRUDA Plus Pemetrexed Combo For Mesothelioma
18 Sep 2024 //
BUSINESSWIRE
New Efti Combination Data To Be Presented For Sarcoma
18 Sep 2024 //
GLOBENEWSWIRE
Antennova`s CD73 Inhibitor Shows 89.5% DCR At ESMO 2024
17 Sep 2024 //
PR NEWSWIRE
PESG Reports On Nuvectis Pharma`s NXP900
16 Sep 2024 //
BUSINESSWIRE
PDS Biotech Announces VERSATILE-002 Results At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
NextCure Presented NC410 Phase 1b Results At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
Keytruda Plus Chemo Reduces Death Risk In Early Breast Cancer
15 Sep 2024 //
BUSINESSWIRE
Keytruda Shows Survival Win In Early Triple-Negative Breast Cancer
15 Sep 2024 //
FIERCE PHARMA
Merck`s KEYTRUDA Demonstrates 10-Year Survival Benefit In Melanoma
15 Sep 2024 //
BUSINESSWIRE
KEYTRUDA Plus CRT Reduces Death Risk In Cervical Cancer By 33%
14 Sep 2024 //
BUSINESSWIRE
KEYTRUDA Plus LENVIMA With TACE Improves PFS In Liver Cancer
14 Sep 2024 //
BUSINESSWIRE
KEYTRUDA Combo Improves OS In HER2+ Gastric Or GEJ Adenocarcinoma
14 Sep 2024 //
BUSINESSWIRE
IO Biotech Announces Positive Phase 2 Results In Head And Neck Cancer
14 Sep 2024 //
GLOBENEWSWIRE
Kintara Therapeutics Updates On Corporate And REM-001 Clinical Study
11 Sep 2024 //
PR NEWSWIRE
Pfizer To Showcase Oncology Portfolio At ESMO 2024
11 Sep 2024 //
BUSINESSWIRE
Incendia Enrolls First Patient In PRTH-101 Phase 1c Trial
10 Sep 2024 //
BUSINESSWIRE
Summit shares hit record high as cancer drug tops Keytruda in China trial
10 Sep 2024 //
BIOSPACE
Gilead`s Trodelvy Triplet Underwhelms But Supports Phase 3 Lung Design
09 Sep 2024 //
FIERCE PHARMA
Akeso, Summit`s PD-1 Bispecific Outperforms Keytruda In Lung Cancer
09 Sep 2024 //
FIERCE PHARMA
Kelun-Biotech Releases Three SKB264 Study Abstracts At ESMO 2024
09 Sep 2024 //
PR NEWSWIRE
Ivonescimab Outperforms Pembrolizumab In First-Line PD-L1+ NSCLC
08 Sep 2024 //
BUSINESSWIRE
Gilead to Present New Trodelvy® Data at IASLC 2024 World Lung Cancer Conference
05 Sep 2024 //
BUSINESSWIRE
Merck to Present New Data on 10 Medicines at ESMO Congress 2024
04 Sep 2024 //
BUSINESSWIRE
EU Approves Merck`s KEYTRUDA and Padcev for Urothelial Carcinoma
03 Sep 2024 //
BUSINESSWIRE
BeyondSpring Presents Plinabulin Data at Lung Cancer Conference and ESMO 2024
03 Sep 2024 //
GLOBENEWSWIRE
IO Biotech Updates On Pivotal Phase 3 Trial Of IO102-IO103 With Keytruda
30 Aug 2024 //
GLOBENEWSWIRE
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
29 Aug 2024 //
BUSINESSWIRE
EC Approves Astellas` PADCEV With KEYTRUDA For Advanced Urothelial Cancer
27 Aug 2024 //
PR NEWSWIRE
GI Innovation To Evaluate GI-102 With KEYTRUDA In Resistant Cancers
26 Aug 2024 //
BUSINESSWIRE
Kineta Reopens VISTA-101 Trial For KVA12123 In Advanced Solid Tumors
19 Aug 2024 //
GLOBENEWSWIRE
Cue Biopharma Reports Q2 2024 Financial Results And Business Highlights
19 Aug 2024 //
GLOBENEWSWIRE
IO Biotech Reports Q2 2024 Results And Business Highlights
13 Aug 2024 //
GLOBENEWSWIRE
Prelude Therapeutics Reports Q2 2024 Results And Corporate Update
12 Aug 2024 //
GLOBENEWSWIRE
Two Ivonescimab Results For NSCLC To Be Presented At WCLC 2024
12 Aug 2024 //
PR NEWSWIRE
Merck Updates On KeyVibe-008 Trial In Small Cell Lung Cancer
09 Aug 2024 //
BIOSPACE
CG Oncology Reports Q2 2024 Results And Provides Business Updates
08 Aug 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
GLOBENEWSWIRE
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024
05 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs Announces FOCUS Phase II Trial Results For UV1
05 Aug 2024 //
GLOBENEWSWIRE
Medicenna Reports Q1 2025 Results And MDNA11 Complete Response
01 Aug 2024 //
GLOBENEWSWIRE
